Industry news · event 2025-08-07 · 3 min read
Orforglipron's Phase 3 Lands: ~12.4% From a Pill With No Food Rules — and a Filing (2025)
Lilly's small-molecule daily GLP-1 reported ATTAIN-1 results in 2025 — about 12.4% average weight loss with none of oral semaglutide's fasting ritual — and headed to the FDA with mass-manufacturing economics.
GRGLP1ProviderCompare Research Team
Pricing & policy research
Quick answerLilly's small-molecule daily GLP-1 reported ATTAIN-1 results in 2025 — about 12.4% average weight loss with none of oral semaglutide's fasting ritual — and headed to the FDA with mass-manufacturing economics.
The most commercially consequential trial readout of 2025 wasn't the biggest number — it was orforglipron's ATTAIN-1: roughly 12.4% average weight loss at 72 weeks from a once-daily small-molecule pill with no food or water restrictions, no injection, and no cold chain.
The pharmacology explains the fuss. Every marketed GLP-1 is a peptide — injectable, or (for oral semaglutide) absorbable only through a strict empty-stomach ritual. Orforglipron is conventional small-molecule chemistry: ordinary tablets, ordinary factories, ordinary shelf life. Its efficacy sits below injectable semaglutide's 14.9% and far below tirzepatide's 20%+, but its manufacturing economics could reset what FDA-approved therapy costs in a way no peptide can.
Lilly filed, and a decision is anticipated in the 2026 window. The strategic reading for the market we track: a cheap, restriction-free approved pill attacks the compounded market's price advantage from above at the same moment regulation squeezes it from below. The full pipeline picture — including retatrutide's 24% and CagriSema — is in the next-generation guide.